What are the indications for osimertinib/osimertinib?

Osimertinib is a targeted drug for non-small cell lung cancer (NSCLC) with specific indications. The following are the main indications of osimertinib/osimertinib:

1.EGFRAdvanced stage with positive gene mutationNSCLC:Osimertinib/OsimertinibIt is mainly used to treat patients with advanced NSCLC who are positive for EGFR gene mutations, especially those who are resistant to first- and second-generation EGFR inhibitors. EGFRmutation is one of the most common markers for targeted therapy in NSCLC, and Osimertinib/Osimertinib has shown significant efficacy in both first-line and second-line treatments.

2.EGFR T790MPositiveNSCLC: Among NSCLC patients, approximately50%of patients will develop resistance after receiving EGFR inhibitor treatment. One of the common resistance mutations is EGFR T790M mutation. Osimertinib/Osimertinib has been shown to have high efficacy in EGFR T790Mpositive NSCLC patients, making it the main treatment option after the development of drug resistance.

3.CNSMetastaticNSCLC:Osimertinib/OsimertinibforEGFRBrain metastasis (CNSmetastasis) in patients with mutation-positive NSCLC has also shown good efficacy. It can penetrate the blood-brain barrier, enter the central nervous system, and inhibit the growth and spread of tumor cells.

In general, osimertinib/osimertinibis a highly effective targeted drug for specific types of NSCLC. It is mainly suitable for patients with advanced NSCLC whose EGFR gene mutations are positive, especially those who are resistant to other EGFR inhibitors or who have EGFR T790MpositiveNSCLC patients. In addition, Osimertinib/Osimertinib is also used to treat brain metastases in NSCLC patients. Before patients receive osimertinib/osimertinib treatment, they should undergo genetic testing to determine whether they meet the indications for the drug. At the same time, the treatment plan should be formulated by the doctor based on the patient's specific situation and medical history.